What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.
Cablivi (caplacizumab-yhdp, Sanofi Genzyme)
Indications: Treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy
Dosage:
Contraindications: Previous severe hypersensitivity reaction to caplacizumab-yhdp or any of the excipients.
FDA Issues CRL for Heplisav-B in Adults With ESRD on Hemodialyis
May 14th 2024Dynavax plans to meet with the FDA to discuss how the company can provide additional data to support the approval of its 4-dose Heplisav-B regimen and expand protection for adults with end-stage renal disease (ESRD) on hemodialysis.